邱錄貴，1964年生，籍貫江西，中國醫(yī)學(xué)科學(xué)院血液病醫(yī)院主任醫(yī)師，博士生導(dǎo)師，實(shí)驗(yàn)血液學(xué)國家重點(diǎn)實(shí)驗(yàn)室一級PI，天津市臍帶血造血干細(xì)胞庫醫(yī)學(xué)主任。1985年畢業(yè)于江西醫(yī)學(xué)院，1991年畢業(yè)于中國協(xié)和醫(yī)科大學(xué)，取得醫(yī)學(xué)碩士學(xué)位，同年就職于中國醫(yī)學(xué)科學(xué)院血液病醫(yī)院；1996-1999年應(yīng)邀于美國路易斯維爾大學(xué)進(jìn)行博士后研究工作；2000年晉升為主任醫(yī)師。主要研究方向?yàn)榱芟的[瘤基礎(chǔ)與精準(zhǔn)干預(yù)策略，是我國淋巴系統(tǒng)腫瘤領(lǐng)域的主要學(xué)科帶頭人之一。

主要研究方向?yàn)榱芟的[瘤基礎(chǔ)與精準(zhǔn)干預(yù)策略。在多發(fā)性骨髓瘤、淋巴瘤、慢性淋巴細(xì)胞白血病以及成人急性淋巴細(xì)胞白血病的精確診斷和預(yù)后分層基礎(chǔ)上的整體治療方面積累了豐富的經(jīng)驗(yàn)，在淋巴系統(tǒng)腫瘤的遺傳學(xué)與分子發(fā)病機(jī)制研究方面取得系列重要成果。

午夜92福利1000,午夜92福利1000,久久国产亚洲高清观看5388,美女不拍网站免费观看,欧美***天天久久综合精品,中文字幕日韩系列中文字幕,综合久久国产九一剧情麻豆,丰满人妻在线免费视频,奶子大逼又嫩操起来真爽

1. Yi S#, Yan Y#, Jin M, Bhattacharya S, Wang Y, Wu Y, Yang L, Gine E, Clot G,Chen L, Yu Y, Zou D, Wang J, Phan AT, Cui R, Li F, Sun Q, Zhai Q, Wang T, Yu Z,Liu L, Liu W, Lyv R, Sui W, Huang W, Xiong W, Wang H, Li C, Xiao Z, Hao M, Wang J, Cheng T, Bea S, Herrera AF, Danilov A, Campo E, Ngo VN, Qiu L*, Wang L*. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J Clin Invest. 2022 Feb 1;132(3):e153283.  (IF: 19.456)

2. Yu Z#, Wei X#, Liu L#, Sun H, Fang T, Wang L, Li Y, Sui W, Wang K, He Y, Zhao Y,Huang W, An G, Meng F, Huang C, Yu T, Anderson KC, Cheng T, Qiu L*, Hao M*.Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in  multiple myeloma. E Bio Medicine. 2022 Apr;78:103950. (IF:11.205)

3. Gang An# , Daobin Zhou , Shu Cheng , Keshu Zhou , Jianyong Li , Jianfeng Zhou , Liping Xie, Jie Jin , Liye Zhong , Lingzhi Yan , Haiyi Guo , Chenmu Du , Jinhua Zhong , Yiling Yu , Binghao Wu , Lugui Qiu* . A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenstr?m Macroglobulinemia. Clin Cancer Res. 2021 Oct 15;27(20):5492-5501. (IF: 12.531)

4. Di Wang# , Jue Wang# , Guang Hu , Wen Wang , Yi Xiao, Haodong Cai , Lijun Jiang , Li Meng , Yongkun Yang , Xiaoxi Zhou , Zhenya Hong , Zheng Yao , Min Xiao, Liting Chen, Xia  Mao , Li Zhu, Jin Wang, Lugui Qiu*, Chunrui Li*, Jianfeng Zhou*. A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2021 May 27;137(21):2890-2901. (IF: 22.133)

5. Yi S#, Yan Y#, Jin M, Xiong W, Yu Z, Yu Y, Cui R, Wang J, Wang Y, Lin Y, Jia Y,Zhang D, Wang T, Lv R, Liu W, Sui W, Huang W, Fu M, Xu Y, Deng S, An G, Zou D,Li Z, Shi J, Xiao Z, Wang J, Cheng T, Gale RP, Wang L*, Qiu L*. High incidence ofMYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia. Leukemia. 2021Aug;35(8):2412-2415. Jan 22. (IF:12.883)

6. Xu Y#, Fulciniti M*, Samur MK, Ho M, Deng S, Liu L, Wen K, Yu T, Chyra Z, Dereibal S, Zhang L, Yao Y, Chakraborty C, Morelli E, Li N, Lopez MA, Perini T, Mu S, An G, Alonso R,Bianchi G, Tai YT, Anderson KC, Qiu L*, Munshi NC*. YWHAE/14-3-3ε expression impacts the protein load contributing to proteasome inhibitor sensitivity in multiple myeloma. Blood. 2020，136(4):468-479. (IF:16.509)

7. An G#*, Yan Y#, Xu Y, Mao X, Liu J, Fan H,Wang Q, Du C, Li Z, Yi S, Lv R, Deng S, Sui W, Fu M, Hao M, Huang W, Zou D, Zhao Y, Yuan C, Du X, Wang J, Cheng T, Tai YT, Munshi NC*, Qiu  L*. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. Leukemia. 2020,34(2):578-588. (IF:11.528)

8. Franqui-Machin R#, Hao M#, Bai H, Gu Z,Zhan X, Habelhah H, Jethava Y, Qiu L*, Frech  I, Tricot G, Zhan F*. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. J Clin Invest. 2018,128(7):2877-2893. (IF:12.87)

9. Qin Y#, Zhang S#, Deng S#, An G, Qin X, Li F, Xu Y, Hao M, Yang Y, Zhou W*, Chang H*, Qiu L*.  Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma. Leukemia. 2017.31(5):123-1135. (IF:11.412)

10. Yi S#, Li Z, Zou D, An G, Cui R, Zhong S, Li H, Xiong W, Li C, Chen W, Liu W, Lv R, Yu Z, Wang H, Xu Y, Zhou K, Ru K, Wang J, Cheng T, Qiu L*. Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia. Genet Med.19(2):182-191. (IF:7.756)